Three years later the FDA finally lifts its hold on Aptose drug, setting the stage for a return to PhIb
After an almost three-year halt imposed by a clinical hold, Aptose Biosciences can finally resume the Phase Ib trial for its MYC inhibitor.
The San …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
